Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.35 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.34 |
| ▸ | MARS1 | P56192 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | ALPL | P05186 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498648 | 0.90 | SHMT1 (0.38) | SHMT1SHMT2NPC1MARS1CNR1 | |
| SCHEMBL6494882 | 0.73 | NPC1 (0.42) | NPC1ALPL | |
| SCHEMBL6070738 | 0.66 | CRHR1 (0.45) | NPC1HPGDDPP4DPP8CRHR1 | |
| SCHEMBL1943591 | 0.63 | EGLN2 (0.49) | NPC1HPGDMARS1CRHR1 | |
| SCHEMBL6500995 | 0.60 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL14014232 | 0.59 | KDM4E (0.53) | NPC1MARS1ALPL | |
| SCHEMBL12680498 | 0.58 | L3MBTL1 (0.50) | L3MBTL1CNR1DPP4DPP8ALPL | |
| SCHEMBL6505240 | 0.58 | NPC1 (0.46) | NPC1 | |
| SCHEMBL12680466 | 0.57 | L3MBTL1 (0.49) | L3MBTL1CNR1DPP4DPP8ALPL | |
| SCHEMBL24425230 | 0.57 | MAPT (0.44) | MARS1CNR1ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958341-B2 | Pyrazolopyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-25 | — | — | US | claimed |
| US-6958341-B2 | Pyrazolopyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-25 | — | — | US | disclosed |
| US-20030139426-A1 | Pyrazolopyrimidines as CRF antagonists | WILDE RICHARD G (US) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139426-A1 | Pyrazolopyrimidines as CRF antagonists | CRHR1, CRHR2, CRH | L3MBTL1 3853/4885SHMT1 3970/4885SHMT2 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.